To evaluate the impact of the starting point on the efficacy of fingolimod treatment in AD, we investigated alterations in weight, behaviour, Aβ load, neuroinflammatory reaction, and BDNF in a mouse model of AD at two different ages. The gene discussed is BDNF; the disease is Alzheimer disease.